Sorafenib Plus SBRT Yields Improved Survival Vs Sorafenib Alone in Locally Advanced HCC
October 25th 2022Stereotactic body radiation therapy is a new standard of care option for patients with locally advanced hepatocellular carcinoma, according to a presentation on the phase 3 NRG/RTOG 1112 trial assessing sorafenib combined with stereotactic body radiation therapy.
Andrew Cook, MD, on the Potential Role of Gabapentin in Head and Neck Cancer
November 5th 2021CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss the potential role of gabapentin in head and neck cancer despite garnering negative results in oropharynx cancer.
Dose-Escalated Radiotherapy Plus STAD Shows Some Benefit for Intermediate-Risk Prostate Cancer
October 27th 2021Although there was no resulting benefit to overall survival with the addition of short-term androgen deprivation to dose-escalated radiotherapy, patients with intermediate-risk prostate cancer experienced other disease benefits with this treatment approach.
Proton Radiotherapy in Patients with LA-NSCLC May Aid in Reducing Risk of Heart Disease
November 14th 2020This study found that found that mini-strokes and heart attacks were significantly less common among patients with locally advanced non-small cell lung cancer who underwent proton therapy versus conventional photon-based radiation therapy.
Patients with Head and Neck Cancer See Impact on Ability to Work Due to Radiotherapy
November 5th 2020In working patients with head and neck cancer receiving radiotherapy, weight loss and an increase in pain, fatigue, and ECOG status were all found to be significantly associated with reductions in working days per week.
Adding Fluciclovine PET to Radiation Treatment Plans for Prostate Cancer Improves Survival
November 4th 2020A study presented at the ASTRO Annual Meeting found that adding the advanced PET radiotracer fluciclovine (Axumin) to conventional imaging for patients with recurrent prostate cancer may improve disease-free survival rates.
Sexual Dysfunction Not Well Addressed in Female Cancer Survivors
November 4th 2020“Sexual dysfunction is an unfortunately common side effect of cancer treatment, and there appears to be a large gender disparity in how physicians discuss sexual health with their patients,” said lead study author James Taylor, MD, MPH.
Study Strengthens Case for SBRT Use in Oligometastatic Neoplasia to the Lung
November 3rd 2020This study indicated that patients with up to 3 lung metastases from primary tumors in other sites who were treated with stereotactic body radiation therapy fared comparably well whether their radiation was delivered in 1 or 4 treatment sessions.
SBRT Appears to be Superior to CRT for Controlling Pain Related to Spinal Metastases
October 31st 2020Stereotactic body radiotherapy may be superior to conventional palliative radiotherapy in improving the complete response rate for pain related to spinal metastases at 3- and 6-months post-radiation.
ctDNA Predicts Outcomes in Lung Cancer Patients Receiving Radiation Therapy
November 14th 2017This peer-to-peer exchange highlights results of a study that tested whether analyzing circulating tumor DNA (ctDNA) during treatment with chemoradiotherapy could predict outcomes in patients with localized lung cancer.
Hypofractionated Regimen Safe, Feasible in Elderly Bladder Cancer Patients
November 8th 2017In this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.